Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

Articles by Seema

20/09/19

Immuneel wants to fight cancer with a radical approach, disruptive pricing & a special team

Seema Singh

10/09/19

Telecom game theory: The cost of an Indian clampdown on Huawei

Seema Singh, Pratap Vikram Singh

12/08/19

Beyond optic(s): Airtel, Vodafone Idea, Jio must play round-robin on fibre

Seema Singh, Pranav Balakrishnan

18/07/19

McKinsey, pharma and the (inexact) art of forecasting: 2020, 2030

Seema Singh, Pranav Balakrishnan

04/07/19

Higher quality, lower costs: India’s cancer grid promise

Seema Singh

24/06/19

India is testing LinkedIn’s talent

Vandana, Seema Singh

29/05/19

Portea Medical’s scale back: A case of misdiagnosing home healthcare?

Seema Singh, Suraksha P

10/05/19

From Uber in SF to Ola in Bengaluru: Ride-sharing’s hidden secret

Seema Singh, Olina Banerji

01/05/19

Manipal to Medanta: Will Ranjan Pai finally break the no-deal jinx?

Seema Singh

09/04/19

Antrix stuck with $1-billion payout, but India’s busy building a Newspace

Seema Singh

29/03/19

Strides, SeQuent, Solara: An Indian entrepreneur’s ingenious pharma spiderweb

Seema Singh

14/02/19

India makes its maiden entry into 5G standards, pisses off big telecoms

Seema Singh

05/02/19

India, the middle kingdom for 5G, is battleground zero for Huawei and Samsung

Seema Singh

07/01/19

Through the Birac-ulors: The odds for India’s only lab-to-market engine

Seema Singh

12/11/18

Bristol-Myers, Roche, Novartis, AZ: Big Pharma’s shrinking club in India

Seema Singh

08/10/18

Practo and the perils of plenty

Seema Singh

31/08/18

Dr Trehan, the last of India’s super-surgeons isn’t done yet. Or perhaps he is

Seema Singh

25/07/18

5G to satellites: All your spectrum are belong to us

Seema Singh

01/07/18

Why the Human Eye is the Window to AI in Healthcare

Seema Singh

25/06/18

Multiples Equity’s bets in healthcare: The dog that didn’t bark

Seema Singh

30/04/18

GSAT-11 delayed; will Isro allow private satellite broadband now?

Seema Singh, Harveen Ahluwalia

02/04/18

Manipal Hospitals-Fortis deal: Groundbreaking or Groundhog Day?

Seema Singh

12/03/18

Up close with cancer: Why Mitra Biotech is looking to Nasdaq

Seema Singh

16/02/18

ION Energy’s race to build a universal battery pack

Seema Singh

26/01/18

Algorithm dynamics: Asking Google, Facebook and others to be ‘fair’

Seema Singh

09/01/18

TeamIndus and Isro call off their GLXP launch contract

Seema Singh

18/12/17

Why rooftops are the sunniest for Amplus and Cleanmax

Seema Singh

04/12/17

Behind Biocon’s Payday

Seema Singh

21/11/17

After the Americans, will half of Indian adults also fall in high BP band?

Ruhi Kandhari, Seema Singh

15/11/17

Mankind Pharma, beyond seductive ads and investor multiples

Seema Singh

30/10/17

You can bring bullet trains from Japan, but not Artificial Intelligence

Seema Singh

06/10/17

One down, nine to go: TeamIndus’ baby step in the giant moonwalk

Seema Singh

03/10/17

The Ken at One

Seema Singh

26/09/17

Indian Pharma’s Perfect Storm – Chinese APIs

Seema Singh, Ruhi Kandhari

11/09/17

On the trail of Gilead’s $1000-pill

Seema Singh

14/08/17

The Advinus Decade: Inside the Tata Group’s expensive drug discovery flameout

Seema Singh

27/07/17

Does TeamIndus still have a shot at its moonshot? Part 2

Seema Singh

26/07/17

Does TeamIndus still have a shot at its moonshot?

Seema Singh

14/07/17

Biopharma is Indian pharma’s next frontier. It is also its Achilles’ heel

Seema Singh

30/06/17

In bad times, a good IPO births a new unicorn

Seema Singh

14/06/17

With the pipe into people’s homes, does healthcare have a chance?

Seema Singh

31/05/17

You can demand mental health now, it’s your right. But be ready for surprises

Seema Singh

26/04/17

A spelling error you can’t do much about. Or can you?

Seema Singh

13/04/17

When wishes became horses–PM Modi’s Silicon Valley playbook

Seema Singh

30/03/17

Check-in, check-out: India’s fast-moving health bureaucracy

Seema Singh, Ruhi Kandhari

20/03/17

The super secretive story of India’s Rs 4500 cr supercomputing mission

Seema Singh

13/03/17

The IPS Media Foundation supports The Ken

Seema Singh

27/02/17

Lost in India—Flu vaccines

Seema Singh

17/02/17

A healthcare business model that most could follow (but don’t)

Seema Singh

23/01/17

Humanising Algorithms

Seema Singh

10/01/17

Curadev’s drug discovery slot machine

Seema Singh

06/01/17

Portea

Seema Singh

02/01/17

Meet India’s Judge Dredd of Dengue

Seema Singh

26/12/16

Spotting health in India’s healthcare

Seema Singh

07/12/16

MedGenome

Seema Singh

06/12/16

One Rocket, Many Satellites: Isro’s final push to India’s commercial space lift-off

Seema Singh

03/12/16

Mitra Biotech

Seema Singh

16/11/16

The mounting NPAs of India’s stem cell banks

Seema Singh

04/11/16

To Moon and Mars, again

Seema Singh

25/10/16

The Great Pharma U-Turn

Seema Singh

13/10/16

SankhyaSutra’s Speed Machine

Seema Singh

04/10/16

A dubious diabetes drug, regulatory confusion, and a potential PIL

Seema Singh

02/09/16

The reinvention of IIT-Madras

Seema Singh

18/08/16

Three things Indian medtech must get right, and one that is still open ended

Seema Singh

10/08/16

Requiem for a dream

Seema Singh

Back to All Writers

See all results for Ken

No results found for Ken.